Skip to main content

Day: December 3, 2021

Nexity: Monthly disclosure of the total number of voting rights and shares – November 2021

NEXITYSociété anonymeau capital de 280 648 620 eurosSiège Social : 19, rue de Vienne – TSA 5002975801 PARIS Cedex 08444 346 795 RCS Paris Monthly disclosure of the total numberof voting rights and shares composing the share capital in accordance with Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés FinanciersInformation cut-off date Total numberof shares Net total number ofvoting rightsNovember 30, 2021   56,129,724   Total gross 56,129,724Net total 55,555,436* Net total = Total number of voting rights attached to the shares – shares without voting rights Paris, December 3, 2021Attachment2021_12_03 – Monthly disclosure of the total number of voting rights and shares – November 2021

Continue reading

Valneva Comments on COV-Boost Clinical Trial Data

Saint Herblain (France), December 3, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today responded to data published from the COV-Boost COVID-19 vaccine trial, which investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines at different dose levels when administered as a third dose, or booster, to people primed with either Pfizer’s Comirnaty or AstraZeneca’s Vaxzevria. The COV-Boost trial, which launched in May 2021 and was led by University Hospital Southampton NHS Foundation Trust, included Valneva’s inactivated, adjuvanted, whole virus COVID-19 vaccine candidate VLA2001. The aim of the COV-Boost trial was to quickly generate data to inform advice from the UK’s Joint Committee on Vaccination and Immunization on the autumn booster campaign. Participants were given a booster...

Continue reading

Changes in the Board of Directors

Professor Dr. Jemilah Mahmood portrait photoPortrait photoBasel, 3 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022. Mr Paul Bulcke, who has been serving on the Board of Directors since 2011, has decided not to stand for re-election at the AGM in 2022, following almost eleven years of tenure. The Board of Directors proposes Dr Jemilah Mahmood, currently the Special Advisor on Public Health to Malaysia’s prime minister, for election to the Board of Directors at the AGM 2022. “As a member of the Board and of the Audit Committee, Paul Bulcke has made significant contributions to Roche’s success,” said Roche Chairman Christoph Franz. “On...

Continue reading

Suominen Corporation: SHARE REPURCHASE 3.12.2021

Suominen Corporation ANNOUNCEMENT 3.12.2021          Suominen Corporation: SHARE REPURCHASE 3.12.2021     In the Helsinki Stock Exchange         Trade date 3.12.2021  Bourse trade Buy  Share SUY1V  Amount 9,602 SharesAverage price/ share 4.8532 EURTotal cost 46,600.43 EUR          Suominen Corporation now holds a total of 835 952 sharesincluding the shares repurchased on 3.12.2021            On behalf of Suominen Corporation       Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For additional information, please contact:  Toni Tamminen, CFO, Suominen Corporation  tel. +358 (0)10 214 3051         www.suominen.fi    AttachmentSuominen 3.12 trades

Continue reading

Vincit Oyj: Omien Osakkeiden Hankinta 3.12.2021

VINCIT OYJ Pörssitiedote 3.12.2021                VINCIT OYJ: OMIEN OSAKKEIDEN HANKINTA 3.12.2021         Helsingin Pörssi             Päivämäärä 3.12.2021    Pörssikauppa Osto    Osakelaji VINCIT    Osakemäärä 2,519 osaketta  Keskihinta/ osake 8.0992 EUR  Kokonaishinta 20,401.88 EUR                Yhtiön hallussa olevat omat osakkeet 3.12.2021  tehtyjen kauppojen jälkeen: 352 012 kpl.                  Vincit Oyj:n puolesta             Nordea Pankki Oyj                    Janne Sarvikivi Sami Huttunen           Lisätietoja:      Vincit Oyj, toimitusjohtaja Julius Manni    puhelin: 050 424 3932                    www.vincit.com             AttachmentVINCIT_3.12_trades

Continue reading

Eolus and a major global energy company increases signed PPA from 68 MW to 117 MW

Hässleholm, Sweden, December 3rd, 2021 On January 13th, 2021, Eolus announced the signing of individual PPAs with a major global energy company for three wind farms in Sweden totaling 68 MW. The agreement covering the individual PPAs have been reworked and the installed capacity have been increased to 117 MW instead. The new overall agreement with the major global energy company covers 100 % of the produced electricity volume in wind farms Skallberget/Utterberget (74 MW), Tjärnäs (25 MW) and Rosenskog (18 MW) in electricity pricing area 3 (SE3) in Sweden. Skallberget/Utterberget and Tjärnäs replaces wind farms Boarp and Dållebo that was part of the initial overall agreement. The PPA for Rosenskog will remain intact. With this change the covered wind farms will total an installed capacity of 117 MW instead of the original 68 MW. The wind...

Continue reading

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS

Anbudsförfarande kommuner och regioner, 2021-12-07Bonds Fixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2026 The following issuers are accepted for delivery: BORÅS KOMMUN GÖTEBORGS KOMMUN HELSINGBORGS KOMMUN JÖNKÖPINGS KOMMUN LINKÖPINGS KOMMUN MALMÖ KOMMUN NORRKÖPINGS KOMMUN SKÅNE LÄNS LANDSTING STOCKHOLMS KOMMUN STOCKHOLMS LÄNS LANDSTING SÖDERTÄLJE KOMMUN UPPSALA KOMMUN VELLINGE KOMMUN VÄSTERÅS KOMMUN     Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-11-26Bids Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se  Bid date 2021-12-07Bid times 10.00-11.00 (CET/CEST) on the Bid dateRequested...

Continue reading

Update on regulatory approvals relating to the voluntary tender offer for Sbanken ASA – Appeal of NCA decision and extension of the Drop Dead Date

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Oslo, 3 December 2021 Reference is made to the offer document dated 23 April 2021 (the “Offer Document”) and subsequent stock exchange announcements, including 24 May 2021 (extension of the Offer Period until 7 June 2021), 7 June 2021 (final extension of Offer Period until 14 June 2021, reduction of minimum acceptance condition to 2/3 and an increase of the Offer Price to NOK 108.85), 1 October 2021 (Adjustment of the Offer Price to NOK 104.45 as a result of a dividend distribution from Sbanken ASA to its shareholders), 28 October 2021 (extension of the Drop Dead Date to 10 December...

Continue reading

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it has received notice of allowance for foundational patent applications for two of its core technologies in several key markets further strengthening the company’s intellectual property. Marizyme also announced today that it has retained the services of Dentons US LLP, the world’s largest law firm with more than 600 international patent lawyers and professionals in more than 80 countries, to manage its global patent portfolio.  Patent applications covering the company’s flagship commercial product, DuraGraft®,have been allowed in Brazil, China and Malaysia....

Continue reading

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in NTG’s shares

Company announcement no. 28 – 213 December 2021 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in NTG’s shares NTG Nordic Transport Group A/S CVR no. 12546106 (“NTG”) hereby announces in accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), to have received the following notification from persons discharging managerial responsibilities in NTG and persons closely associated with them in NTG’s shares and other financial instruments linked thereto: Karen-Marie Katholm (Board member)Karen-Marie Katholm has on 2 December 2021 purchased 1,000 shares in NTG of nominally DKK 20 each at a price of DKK 441.5 per share. Reference is made to the attached...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.